Researchers Evaluate Whether Aquatic Exercise Is Most Effective Therapy for IA
June 1st 2022Research supports that aquatic exercise is effective at reducing pain and disease activity and improving physical function, although it is unclear whether it is more effective than any other form of therapy for inflammatory arthritis (IA).
Read More
Food Sensitization in Early-Onset AD Linked With Later Allergic Respiratory Diseases
May 31st 2022Pediatric patients with early-onset atopic dermatitis (AD) who reported incidence of food sensitization were associated with later allergic respiratory diseases, in which persistence of AD was linked with multiple food allergies.
Read More
FDA Approves Tisa-Cel for Third Indication, R/R Follicular Lymphoma
May 31st 2022Tisagenlecleucel (tisa-cel) was approved to treat adults with relapsed or refractory (R/R) follicular lymphoma. This is the third indication for the therapy since it became the first FDA-approved chimeric antigen receptor T-cell therapy in 2017.
Read More
Fully Artificial Pancreas Produces Results Comparable With Hybrid Artificial Pancreas
May 31st 2022This new study from Canada compared outcomes in patients living with type 1 diabetes who used 2 closed-loop insulin delivery systems: a fully artificial pancreas that did not require meal input and a hybrid artificial pancreas that required carbohydrate counting.
Read More
Medicare recipients will see a reduction in premium costs in 2023, although the amount has not yet been announced; the FDA is investigating a hepatitis A outbreak potentially linked to organic strawberries sold by FreshKampo and HEB; approximately 20,640 American adults will be diagnosed with esophageal cancer in 2022, data suggest.
Read More
Genetic Risk Scores for Alzheimer Disease May Have Implications for Parkinson Disease
May 30th 2022The findings from the study indicate that higher genetic risk score for Alzheimer disease (AD) are associated with cognitive declines in patients with Parkinson disease (PD), while higher genetic risk scores for PD signify an increased risk of PD, albeit with slower clinical progression after diagnosis.
Read More
Study Finds Adjuvant Therapy Beneficial for Distal Cholangiocarcinoma With Lymph Node Metastasis
May 29th 2022Recurrence is common in patients with distal cholangiocarcinoma, even after curative surgical resection. In a recent study, postoperative adjuvant therapy correlated with improved survival, but only in certain patients.
Read More
Unmet Need Remains in iTTP Treatment, but Caplacizumab Could Be Major Step Forward
May 28th 2022A panel of experts suggests adding caplacizumab to the historic treatment of plasma exchange and immunosuppression could lead to significant improvement in outcomes for patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP).
Read More
Researchers Establish, Validate Prognostic Model for Uveal Melanoma
May 28th 2022The model consists of 3 metabolism-related genes—carbonic anhydrase 12, acyl-CoA synthetase long-chain family member 3, and synaptojanin 2— that the researchers said could potentially be used as biomarkers and treatment targets in the disease.
Read More
Nivolumab-Based Combos Approved in First-line Advanced ESCC
May 28th 2022The approvals were announced by Bristol Myers Squibb (BMS), maker of the 2 immunotherapy treatments approved for 1 combination: nivolumab (Opdivo), the first approved PD-1 immune checkpoint inhibitor, and ipilimumab (Yervoy), which activates the immune system by targeting CTLA-4.
Read More
Real-world Efficacy of Risankizumab in Psoriasis Shown for Patients With Prior Biologic Failure
May 28th 2022Real-world patients with moderate to severe plaque psoriasis who had experienced prior biologic failure demonstrated significant improvement and an adequate safety profile with risankizumab treatment.
Read More